SAS Provides BioMimetic Therapeutics, Inc. With Serious Analytics for Clinical Trials

March 10, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

CARY, N.C.--(BUSINESS WIRE)--SAS, the leader in business analytics, will provide bio-assay analyses and sophisticated visualization capabilities for BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) through SAS Visual Data Discovery for Midsize Business.

Twitter
LinkedIn
Facebook
Email
Print

Alliances